Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States
Jacie T. Cooper, John E. Schneider, Thomas Mclain, Steven Coca, Michael J. Donovan · 2026
Read Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States by Jacie T. Cooper, John E. Schneider, Thomas Mclain, Steven Coca, Michael J. Donovan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13548659.txt.
Description
Jacie T. Cooper and colleagues model whether a biomarker-based kidney risk score pays for itself in American Medicare patients, in a 2026 cost-effectiveness analysis. Diabetic kidney disease drives nearly half of new kidney failure, and protective drugs stay underused because standard staging sorts patients crudely. The KidneyIntelX score blends biomarkers with artificial intelligence to predict rapid decline, steering drug treatment toward those likeliest to progress.
Simulating lifetimes for patients in early disease stages, score-guided care produced fewer kidney failures, heart events, dialysis starts, and transplants than staging-guided care. Patients spent less time in advanced stages, gained a small amount of quality-adjusted life, and cost Medicare roughly five hundred dollars less each. Adding a second drug class widened the savings slightly. The authors call wide deployment a dominant strategy: better and cheaper at once.
Catalog record
| CREATOR | Jacie T. Cooper, John E. Schneider, Thomas Mclain, Steven Coca, Michael J. Donovan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62752 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |